Metformin and Zolpidem Interaction: What Patients and Clinicians Need to Know

Is There a Direct Interaction Between Metformin and Zolpidem?

Immediate-release metformin is an oral biguanide indicated, with diet and exercise, to improve glycemic control in adults and children 10 and older with type 2 diabetes [1]. Its label describes it as not metabolized, negligibly bound to plasma proteins, and cleared by the kidneys [1]. Zolpidem is a sedative-hypnotic and a GABA-A receptor positive modulator, indicated for short-term treatment of insomnia with difficulty falling asleep [2]. Its exposure depends on CYP3A4: rifampin cut zolpidem AUC by 73% and half-life by 36%, while ketoconazole raised AUC by 70% and peak level by 30% [2].

The metformin label's interaction table names carbonic anhydrase inhibitors such as topiramate and zonisamide, drugs that reduce metformin clearance through OCT2 and MATE transporters (ranolazine, vandetanib, dolutegravir, cimetidine), alcohol, insulin and insulin secretagogues, and drugs that tend to raise glucose [1]. Zolpidem is not on it. The Ambien label's interaction section names alcohol and other CNS depressants, opioids, imipramine, chlorpromazine, sertraline, fluoxetine, haloperidol, the CYP3A4 inducers rifampin and St. John's wort, and the inhibitor ketoconazole [2]. Metformin is not on it.

What Actually Matters at Night

The metformin label's hypoglycemia warning is specific. Risk increases when metformin is used with insulin or an insulin secretagogue, and lower doses of those drugs may be needed [1]. In the label's trial of 141 patients on metformin up to 2,550 mg a day versus 145 on placebo, hypoglycemia was among the reactions reported in 1% to 5% of metformin patients [1].

Zolpidem's label focuses on the brain, not glucose. It carries a boxed warning for complex sleep behaviors (sleep-walking, sleep-driving, preparing and eating food, making phone calls, having sex), which can happen after the first or any dose, at recommended doses, with or without alcohol, and have caused serious injury and death [2]. The label also warns of impaired alertness and coordination, including next-morning impairment, with risk rising with dose, with less than 7 to 8 hours of sleep remaining, with alcohol and other CNS depressants, and with drugs that raise zolpidem levels [2]. FDA notes that patients can be impaired the morning after even when they feel fully awake [3].

Doses the Labels Specify

For zolpidem, the recommended initial dose is a single 5 mg for women and 5 or 10 mg for men, taken once per night immediately before bed with at least 7 to 8 hours left before the planned time of awakening [2]. The total dose should not exceed 10 mg once daily, and it should not be re-administered during the same night [2]. Geriatric patients and people with mild to moderate liver impairment are recommended 5 mg [2]. Ambien CR starts at 6.25 mg for women and 6.25 or 12.5 mg for men [2][4]. FDA required the lower women's doses in January 2013 because blood levels in some patients may be high enough the next morning to impair driving, and women clear zolpidem more slowly than men [3].

For metformin, immediate-release tablets start at 500 mg twice daily or 850 mg once daily with meals and top out at 2,550 mg a day in divided doses [1]. Extended-release tablets start at 500 mg once daily with the evening meal, are swallowed whole, and top out at 2,000 mg once daily [5].

Kidney Function and Age

Metformin is the drug in this pair whose handling depends on the kidneys. The label calls for an eGFR before starting and at least yearly afterward, contraindicates the drug below 30 mL/min/1.73 m2, does not recommend starting it at 30 to 45, and says to reassess benefit and risk if eGFR later falls below 45 [1]. Zolpidem needs no dose adjustment for kidney function; the label's adjustments are for age and liver impairment [2].

For adults 65 and older, the American Geriatrics Society 2023 Beers Criteria recommend avoiding zolpidem and the other Z-drugs, citing delirium, falls, fractures and crashes with minimal sleep benefit [6]. Metformin's label asks for more frequent renal assessment in older patients [1].

Alcohol Is the One Substance Both Labels Address

Alcohol potentiates metformin's effect on lactate metabolism, and the metformin label says patients should be warned against excessive intake [1]. With zolpidem, alcohol produced an additive effect on psychomotor performance in a direct interaction study [2]. Each label carries its own alcohol warning.

Other Label Warnings

For Ambien, the label says to discontinue it immediately if a complex sleep behavior occurs, and the drug is contraindicated in anyone who has had one [2]. Angioedema and anaphylaxis have been reported after the first or later doses, and the label says not to rechallenge [2].

For metformin, the boxed warning is lactic acidosis. Postmarketing cases were often subtle at onset (malaise, myalgias, respiratory distress, somnolence, abdominal pain), with blood lactate above 5 mmol/L and metformin plasma levels generally above 5 mcg/mL [1]. The label names renal impairment, age 65 or older, radiologic contrast studies, surgery and other procedures, hypoxic states, excessive alcohol intake, hepatic impairment and carbonic anhydrase inhibitors as risk factors [1]. Separately, the label reports subnormal B12 in about 7% of patients in 29-week trials and asks for hematologic parameters annually and vitamin B12 at 2 to 3 year intervals [1].

If Insomnia Needs Treating

The American College of Physicians recommends cognitive behavioral therapy for insomnia as the initial treatment for chronic insomnia in all adults, with medication added through shared decision-making if CBT-I alone does not work [7]. Zolpidem's approved use is short-term, and the label says treatment should be as short as possible and that insomnia persisting after 7 to 10 days should be re-evaluated [2].